NBRV vs. BDTX, NLTX, SLS, BIOA, CLLS, FTLF, CRBU, BTMD, KYTX, and TVGN
Should you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Black Diamond Therapeutics (BDTX), Neoleukin Therapeutics (NLTX), SELLAS Life Sciences Group (SLS), BioAge Labs (BIOA), Cellectis (CLLS), FitLife Brands (FTLF), Caribou Biosciences (CRBU), biote (BTMD), Kyverna Therapeutics (KYTX), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry.
Nabriva Therapeutics vs. Its Competitors
Nabriva Therapeutics (NASDAQ:NBRV) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Black Diamond Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Black Diamond Therapeutics' return on equity of 12.70% beat Nabriva Therapeutics' return on equity.
0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by company insiders. Comparatively, 6.0% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 2 mentions for Black Diamond Therapeutics and 0 mentions for Nabriva Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.79 beat Nabriva Therapeutics' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
Black Diamond Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 248.26%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Nabriva Therapeutics.
Nabriva Therapeutics has higher revenue and earnings than Black Diamond Therapeutics. Nabriva Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the S&P 500.
Summary
Black Diamond Therapeutics beats Nabriva Therapeutics on 14 of the 16 factors compared between the two stocks.
Get Nabriva Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nabriva Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NBRV) was last updated on 9/18/2025 by MarketBeat.com Staff
Free NBRV Stock Alerts